Pharmaceutical

ConSynance wins FDA designation for Prader-Willi syndrome therapy

A Phase II study for ConSynance’s triple monoamine reuptake inhibitor CSTI-500 is slated to begin in 2025.

Jul 26, 2024 - 04:00
ConSynance wins FDA designation for Prader-Willi syndrome therapy
A Phase II study for ConSynance’s triple monoamine reuptake inhibitor CSTI-500 is slated to begin in 2025.
Read the original article

Tags:

Previous Article

Sandoz launches ustekinumab biosimilar in Europe 

Next Article

FDA agrees wider use of BioMarin’s BRINEURA for CLN2

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA approves AstraZeneca, Ionis treatment for rare nerve disease

STAT+: FDA approves AstraZeneca, Ionis treatment for ra...

Dec 23, 2023

STAT+: Backed by Mayo Clinic and Microsoft, a nonprofit forms to test AI tools used in health care

STAT+: Backed by Mayo Clinic and Microsoft, a nonprofit...

Jan 8, 2024

Opinion: Listen: The true costs of mediocre insurance plans for medical students

Opinion: Listen: The true costs of mediocre insurance p...

Nov 15, 2023